|
GB202103563D0
|
|
Treatment for autoimmune diseases
|
|
GB202100988D0
|
|
Naltrexone Compositions
|
|
GB202003644D0
|
|
Treatment for autoimmune diseases
|
|
WO2020178446A1
|
|
Method of monitoring treatment
|
|
WO2020178447A1
|
|
Method for determining efficacy
|
|
GB202002038D0
|
|
Compounds for treating bone disorders
|
|
GB201903546D0
|
|
Cancer treatment
|
|
GB201903547D0
|
|
Treatment for autoimmune diseases
|
|
GB201805206D0
|
|
Autoimmune therapy II
|
|
GB201805207D0
|
|
Autoimmune therapy
|
|
AU2018244806A1
|
|
An agent that increases the expression of the Bcl2-associated agonist of cell death for the treatment of cancer
|
|
GB201718806D0
|
|
Breast cancer treatment
|
|
EP3482751A1
|
|
Cancer treatment
|
|
GB201704909D0
|
|
Cancer therapy
|
|
GB201704910D0
|
|
High dose combi I
|
|
GB201704911D0
|
|
High dose combo I
|
|
GB201704908D0
|
|
Autoimmune therapy I
|
|
GB201704912D0
|
|
Autoimmune therapy II
|
|
GB201704913D0
|
|
Method
|
